A Study To Assess The Effect Of PF-03526299 On Lung Function Following An Allergen Challenge In Asthmatic Subjects

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: All

Summary

PF-03526299, a novel anti-inflammatory agent should attenuate the effect of a bronchial allergen challenge on lung function and hence provide proof of mechanism for this agent.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Fluticasone; Xhance

Criteria

Inclusion Criteria:

• Males and females 18-60 years

• Mild asthma

• Atopic to allergens

Exclusion Criteria:

• Unstable asthma

• Smokers or recent ex-smokers

• Recent allergen challenge